254 related articles for article (PubMed ID: 31971032)
1. Pretreatment SUV
Strati P; Ahmed MA; Nastoupil LJ; Feng L; Hagemeister FB; Fayad LE; Rodriguez MA; Samaniego F; Wang M; Westin JR; Lee HJ; Iyer SP; Parmar S; Ahmed S; Nair R; Steiner RE; Noorani M; Flowers CR; Davis RE; Fowler NH; Neelapu SS
Leuk Lymphoma; 2020 Jun; 61(6):1380-1387. PubMed ID: 31971032
[TBL] [Abstract][Full Text] [Related]
2. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
3. Ki67 proliferation index in follicular lymphoma is associated with favorable outcome in patients treated with R-CHOP.
Nichols MM; Ondrejka SL; Patil S; Durkin L; Hill BT; Hsi ED
Leuk Lymphoma; 2023; 64(8):1433-1441. PubMed ID: 37226602
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
[TBL] [Abstract][Full Text] [Related]
6. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
7. Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
Watanabe T; Matsuno Y; Wakabayashi M; Maruyama D; Yamamoto K; Kubota N; Shimada K; Asagoe K; Yamaguchi M; Ando K; Ogura M; Kuroda J; Suehiro Y; Tsukasaki K; Tobinai K; Nagai H
Hematol Oncol; 2024 May; 42(3):e3272. PubMed ID: 38595316
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
Press OW; Unger JM; Rimsza LM; Friedberg JW; LeBlanc M; Czuczman MS; Kaminski M; Braziel RM; Spier C; Gopal AK; Maloney DG; Cheson BD; Dakhil SR; Miller TP; Fisher RI
J Clin Oncol; 2013 Jan; 31(3):314-20. PubMed ID: 23233710
[TBL] [Abstract][Full Text] [Related]
9. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.
Cheah CY; Chihara D; Ahmed M; Davis RE; Nastoupil LJ; Phansalkar K; Hagemeister FB; Fayad LE; Westin JR; Oki Y; Fanale MA; Romaguera JE; Wang ML; Lee H; Turturro F; Samaniego F; Rodriguez MA; Neelapu SS; Fowler NH
Ann Oncol; 2016 May; 27(5):895-901. PubMed ID: 26802151
[TBL] [Abstract][Full Text] [Related]
11. Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up.
Soini EJO; Martikainen JA; Nousiainen T
Ann Oncol; 2011 May; 22(5):1189-1197. PubMed ID: 21135053
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
Luminari S; Ferrari A; Manni M; Dondi A; Chiarenza A; Merli F; Rusconi C; Tarantino V; Tucci A; Vitolo U; Kovalchuk S; Angelucci E; Pulsoni A; Arcaini L; Angrilli F; Gaidano G; Stelitano C; Bertoldero G; Cascavilla N; Salvi F; Ferreri AJM; Vallisa D; Marcheselli L; Federico M
J Clin Oncol; 2018 Mar; 36(7):689-696. PubMed ID: 29095677
[TBL] [Abstract][Full Text] [Related]
13. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Hiddemann W; Kneba M; Dreyling M; Schmitz N; Lengfelder E; Schmits R; Reiser M; Metzner B; Harder H; Hegewisch-Becker S; Fischer T; Kropff M; Reis HE; Freund M; Wörmann B; Fuchs R; Planker M; Schimke J; Eimermacher H; Trümper L; Aldaoud A; Parwaresch R; Unterhalt M
Blood; 2005 Dec; 106(12):3725-32. PubMed ID: 16123223
[TBL] [Abstract][Full Text] [Related]
14. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
Hill BT; Nastoupil L; Winter AM; Becnel MR; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Fakhri B; Reddy P; Smith SD; Mukhija D; Jagadeesh D; Desai A; Alderuccio JP; Lossos IS; Mehra P; Portell CA; Goldman ML; Calzada O; Cohen JB; Hussain MJ; Ghosh N; Caimi P; Tiutan T; Martin P; Kodali A; Evens AM; Kahl BS
Br J Haematol; 2019 Feb; 184(4):524-535. PubMed ID: 30575016
[TBL] [Abstract][Full Text] [Related]
15. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
16. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma.
Claustre G; Boulanger C; Maloisel F; Etienne-Selloum N; Fornecker LM; Durot E; Slimano F; Graff V
J Cancer Res Clin Oncol; 2023 May; 149(5):1883-1893. PubMed ID: 35789429
[TBL] [Abstract][Full Text] [Related]
18. Impact of age on clinical risk scores in follicular lymphoma.
Alig S; Jurinovic V; Pastore A; Haebe S; Schmidt C; Zoellner AK; Dreyling M; Unterhalt M; Hoster E; Hiddemann W; Weigert O
Blood Adv; 2019 Apr; 3(7):1033-1038. PubMed ID: 30940638
[TBL] [Abstract][Full Text] [Related]
19. Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma.
Tomita N; Takasaki H; Fujisawa S; Miyashita K; Ogusa E; Kishimoto K; Matsuura S; Sakai R; Koharazawa H; Yamamoto W; Fujimaki K; Fujita H; Ishii Y; Taguchi J; Kuwabara H; Motomura S; Ishigatsubo Y
J Clin Exp Hematop; 2013; 53(2):121-5. PubMed ID: 23995108
[TBL] [Abstract][Full Text] [Related]
20. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
Federico M; Luminari S; Dondi A; Tucci A; Vitolo U; Rigacci L; Di Raimondo F; Carella AM; Pulsoni A; Merli F; Arcaini L; Angrilli F; Stelitano C; Gaidano G; Dell'olio M; Marcheselli L; Franco V; Galimberti S; Sacchi S; Brugiatelli M
J Clin Oncol; 2013 Apr; 31(12):1506-13. PubMed ID: 23530110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
